Brief: Eisai Submits Marketing Authorisation Variation To EMA For Intravenous Maintenance Dosing With Leqembi
26/01/2026 21:03
Jan 26 (Reuters) - Bioarctic Ab BIOAb.ST: EISAI SUBMITS MARKETING AUTHORISATION VARIATION TO EMA FOR INTRAVENOUS MAINTENANCE DOSING EVERY FOUR WEEKS WITH LEQEMBI® (LECANEMAB) Source text: ID:nWkr9RC9Z8 Further company coverage: BIOAb.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China